» Articles » PMID: 18079277

State- and Use-dependent Block of Muscle Nav1.4 and Neuronal Nav1.7 Voltage-gated Na+ Channel Isoforms by Ranolazine

Overview
Journal Mol Pharmacol
Date 2007 Dec 15
PMID 18079277
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Ranolazine is an antianginal agent that targets a number of ion channels in the heart, including cardiac voltage-gated Na(+) channels. However, ranolazine block of muscle and neuronal Na(+) channel isoforms has not been examined. We compared the state- and use-dependent ranolazine block of Na(+) currents carried by muscle Nav1.4, cardiac Nav1.5, and neuronal Nav1.7 isoforms expressed in human embryonic kidney 293T cells. Resting and inactivated block of Na(+) channels by ranolazine were generally weak, with a 50% inhibitory concentration (IC(50)) >/= 60 microM. Use-dependent block of Na(+) channel isoforms by ranolazine during repetitive pulses (+50 mV/10 ms at 5 Hz) was strong at 100 microM, up to 77% peak current reduction for Nav1.4, 67% for Nav1.5, and 83% for Nav1.7. In addition, we found conspicuous time-dependent block of inactivation-deficient Nav1.4, Nav1.5, and Nav1.7 Na(+) currents by ranolazine with estimated IC(50) values of 2.4, 6.2, and 1.7 microM, respectively. On- and off-rates of ranolazine were 8.2 microM(-1) s(-1) and 22 s(-1), respectively, for Nav1.4 open channels and 7.1 microM(-1) s(-1) and 14 s(-1), respectively, for Nav1.7 counterparts. A F1579K mutation at the local anesthetic receptor of inactivation-deficient Nav1.4 Na(+) channels reduced the potency of ranolazine approximately 17-fold. We conclude that: 1) both muscle and neuronal Na(+) channels are as sensitive to ranolazine block as their cardiac counterparts; 2) at its therapeutic plasma concentrations, ranolazine interacts predominantly with the open but not resting or inactivated Na(+) channels; and 3) ranolazine block of open Na(+) channels is via the conserved local anesthetic receptor albeit with a relatively slow on-rate.

Citing Articles

Ranolazine Attenuates Brain Inflammation in a Rat Model of Type 2 Diabetes.

Cassano V, Tallarico M, Armentaro G, De Sarro C, Iannone M, Leo A Int J Mol Sci. 2022; 23(24).

PMID: 36555798 PMC: 9782607. DOI: 10.3390/ijms232416160.


Ranolazine: An Old Drug with Emerging Potential; Lessons from Pre-Clinical and Clinical Investigations for Possible Repositioning.

Rouhana S, Virsolvy A, Fares N, Richard S, Thireau J Pharmaceuticals (Basel). 2022; 15(1).

PMID: 35056088 PMC: 8777683. DOI: 10.3390/ph15010031.


The Evidence for Sparsentan-Mediated Inhibition of and : Possibly Unlinked to Its Antagonism of Angiotensin II or Endothelin Type a Receptor.

Chuang T, Cho H, Wu S Biomedicines. 2022; 10(1).

PMID: 35052766 PMC: 8773265. DOI: 10.3390/biomedicines10010086.


Block of Voltage-Gated Sodium Channels as a Potential Novel Anti-cancer Mechanism of TIC10.

Fuchs E, Messerer D, Karpel-Massler G, Fauler M, Zimmer T, Jungwirth B Front Pharmacol. 2021; 12:737637.

PMID: 34744721 PMC: 8567104. DOI: 10.3389/fphar.2021.737637.


Targeted Therapies for Skeletal Muscle Ion Channelopathies: Systematic Review and Steps Towards Precision Medicine.

Desaphy J, Altamura C, Vicart S, Fontaine B J Neuromuscul Dis. 2020; 8(3):357-381.

PMID: 33325393 PMC: 8203248. DOI: 10.3233/JND-200582.


References
1.
Song Y, Shryock J, Wu L, Belardinelli L . Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol. 2004; 44(2):192-9. DOI: 10.1097/00005344-200408000-00008. View

2.
Wang S, Bonner K, Russell C, Wang G . Tryptophan scanning of D1S6 and D4S6 C-termini in voltage-gated sodium channels. Biophys J. 2003; 85(2):911-20. PMC: 1303212. DOI: 10.1016/S0006-3495(03)74530-5. View

3.
Wang S, Mitchell J, Moczydlowski E, Wang G . Block of inactivation-deficient Na+ channels by local anesthetics in stably transfected mammalian cells: evidence for drug binding along the activation pathway. J Gen Physiol. 2004; 124(6):691-701. PMC: 2234030. DOI: 10.1085/jgp.200409128. View

4.
Hille B . Local anesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction. J Gen Physiol. 1977; 69(4):497-515. PMC: 2215053. DOI: 10.1085/jgp.69.4.497. View

5.
Klugbauer N, Lacinova L, Flockerzi V, Hofmann F . Structure and functional expression of a new member of the tetrodotoxin-sensitive voltage-activated sodium channel family from human neuroendocrine cells. EMBO J. 1995; 14(6):1084-90. PMC: 398185. DOI: 10.1002/j.1460-2075.1995.tb07091.x. View